News for Akeso, Inc. (9926.HK)

Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced the grant of inducement awards of options to purchase a collective t

HONG KONG, June 5, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ('Akeso' or the 'Company') is pleased to announce that the National Medical Products Administration (NMPA) has approved the company's first- in-class PD-1/CTLA-4 bispecific antibody, cadonilimab, for the first-line treatment of persistent, recurrent, or metastatic cervical cancer, in combination with platinum-based chemotherapy, with or without bevacizumab. The NMPA approval marks the third approved indication for cadonilimab.

Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on its operational progre

Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories.

HONG KONG, April 25, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ('Akeso' or the 'Company') is excited to announce that the U.S. Food and Drug Administration (FDA) has approved its differentiated PD-1 monoclonal antibody, penpulimab-kcqx, in combination with cisplatin or carboplatin and gemcitabine for the first-line treatment of adult recurrent or metastatic non-keratinizing nasopharyngeal carcinoma (NPC). FDA also approved penpulimab-kcqx as a single agent for adults with metastatic non-keratinizing NPC with disease progression on or after platinum-based chemotherapy and with least one other prior line of therapy. Penpulimab-kcqx was developed independently by Akeso, with further development and commercialization managed through a joint venture with Chia Tai-Tianqing Pharmaceutical Group.

Summary Summit Therapeutics Inc (SMMT), a biopharmaceutical company specializing in oncology, has announced that it will host an earnings call to discuss its fi

The HARMONi-6 trial demonstrates a statistically significant improvement in progression-free survival (PFS) with ivonescimab plus chemotherapy over tisleli

Investment Highlights: Akeso, Inc. is currently undervalued at its trading price of HK$82.95. The company's intrinsic value is estimated at HK$122.47, in

HONG KONG, April 18, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ('Akeso' or the 'Company') is pleased to announce that ebdarokimab, an investigational monoclonal antibody developed by the company, has received marketing approval from the National Medical Products Administration (NMPA) for the treatment of moderate-to-severe plaque psoriasis in adult patients.

A potential U.S. launch of this Chinese biotech's new lung cancer drug - which bested Merck's blockbuster Keytruda - is a key future catalyst.

Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced the grant of inducement awards of options to purchase a collective t

Key Highlights:

Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced the grant of inducement awards of options to purchase a collective t

HONG KONG, March 21, 2025 /PRNewswire/ -- Akeso Inc. (9926.HK) presented promising phase III safety run-in results from the COMPASSION-18/AK104-305 study, at the 2025 Annual Meeting of the Society of Gynecologic Oncology (SGO). The study evaluates the global first-in-class PD-1/CTLA-4 bispecific antibody, cadonilimab (AK104), in combination with concurrent chemoradiotherapy (CCRT) for the treatment of locally advanced cervical cancer.

Summit Therapeutics Inc. (NASDAQ: SMMT) (”œSummit,” ”œwe,” or the ”œCompany”) today announced that Robert LaCaze has joined Summit Therapeutics as Chi

HONG KONG, March 17, 2025 /PRNewswire/ -- Akeso Inc. (9926.HK) announced that its innovative, self-developed anti-PD-1 monoclonal antibody, penpulimab, has been officially approved by the National Medical Products Administration (NMPA) for the first-line treatment of recurrent or metastatic nasopharyngeal cancer (NPC) in combination with chemotherapy.

Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced the grant of inducement awards of options to purchase a collective t

We recently compiled a list of the 10 Hot Growth Stocks to Invest in According to Analysts. In this article, we are going to take a look at where Summit Therapeutics Inc.

HONG KONG, March 7, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ('Akeso' or the 'Company') is excited to announce that the groundbreaking results of the Phase III clinical study (HARMONi-2/AK112-303) of its first-in-class PD-1/VEGF bispecific antibody, ivonescimab, as a monotherapy compared to pembrolizumab monotherapy in the first-line treatment of PD-L1 positive (PD-L1 TPS ≥1%) locally advanced or metastatic non-small cell lung cancer (NSCLC) have been published in The Lancet.